Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24361248 | 0.82 | TSHR (0.34) | TSHRALDH1A1MAPK1GAANR1H3 | |
| SCHEMBL19501019 | 0.82 | TSHR (0.34) | TSHRALDH1A1MAPK1GAANR1H3 | |
| SCHEMBL14770904 | 0.80 | TSHR (0.33) | TSHRALDH1A1MAPK1GAANR1H3 | |
| SCHEMBL17487351 | 0.73 | — | — | |
| SCHEMBL14760149 | 0.73 | TSHR (0.39) | TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL9563367 | 0.70 | GAA (0.33) | TSHRALDH1A1TDP1MAPK1GAA | |
| SCHEMBL22334184 | 0.69 | — | — | |
| SCHEMBL16786174 | 0.69 | TSHR (0.38) | TSHR | |
| SCHEMBL27709697 | 0.68 | TSHR (0.35) | TSHRALDH1A1TDP1MAPK1 | |
| SCHEMBL28774470 | 0.66 | TSHR (0.33) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, LLC | 2023-06-22 | — | — | US | disclosed |
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022701-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CYP21A2, CYP24A1, HSD17B2 | TSHR 1554/4885ALDH1A1 1548/4885TDP1 3247/4885 |
| US-20230192756-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | TSHR 448/4885ALDH1A1 1160/4885TDP1 4382/4885 |
| US-20150158903-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | CHRNB4, CHRNB3, MC2R | TSHR 448/4885ALDH1A1 1160/4885TDP1 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.